Search results for " biomarkers"

showing 10 items of 365 documents

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

2013

Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms of folate pathway genes for pemetrexed metabolism have not been fully elucidated yet. The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. miR-22, miR-24, …

MaleGuanineSettore MED/06 - Oncologia MedicaPemetrexedMiddle AgedNeoplastic Cells CirculatingPrognosisBiomarkers PharmacologicalNon-Small Cell Lung CancerGene Expression Regulation NeoplasticMicroRNAsGlutamatesCarcinoma Non-Small-Cell LungBiomarkers TumorNon-Small Cell Lung Cancer; BiomarkersHumansFemaleBiomarkersAgedNeoplasm Staging
researchProduct

Protein oxidation in chronic kidney disease.

2013

An imbalance between oxidative processes and antioxidant systems has been widely demonstrated in chronic kidney diseases (CKD). In this study we enrolled 26 healthy subjects, 27 patients with CKD on conservative treatment (CT-CKD) with various degrees of renal failure, and 31 CKD subjects in haemodialysis treatment (HD-CKD), evaluated before and after a standard haemodialysis session. In each group we measured protein carbonyl groups (PC) as an index of protein oxidation, lipid peroxidation (TBARS) and two plasma markers of leukocyte activation, elastase and myeloperoxidase (MPO). In CT-CKD subjects the PC level was significantly higher than in normal controls, and it was negatively correla…

MaleHEMODIALYSISmedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyBIOMARKERSRenal functionurologic and male genital diseasesProtein oxidationThiobarbituric Acid Reactive SubstancesLipid peroxidationDiabetes Complicationschemistry.chemical_compoundCARBONYL STRESSMARKERSINFLAMMATIONGlycationRenal DialysisPhysiology (medical)Internal medicinemedicineTBARSHumansRenal Insufficiency ChronicPeroxidasebiologyPancreatic Elastasebusiness.industryNITRIC-OXIDE METABOLITESElastaseHematologyMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsOxidative StressEndocrinologychemistryMyeloperoxidaseNITRIC-OXIDE METABOLITES; CHRONIC-RENAL-FAILURE; CARBONYL STRESS; HEMODIALYSIS; BIOMARKERS; MARKERS; INFLAMMATIONImmunologybiology.proteinFemaleCHRONIC-RENAL-FAILURELipid PeroxidationCardiology and Cardiovascular MedicinebusinessOxidation-ReductionKidney diseaseClinical hemorheology and microcirculation
researchProduct

Novel mutations of CETP gene in Italian subjects with hyeralphalipoproteinemia

2009

Abstract Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that catalyses the transfer of cholesteryl esters from HDL to the other plasma lipoproteins. Genetic deficiency of CETP is one of the known causes of elevation of plasma HDL-C (primary hyperalphalipoproteinemia, HALP). We sequenced CETP gene in a group of 24 Italian subjects with primary HALP (HDL-C>80 mg/dl) suspected to have CETP deficiency. Two unrelated subjects both coming from the same geographical district, were found to be heterozygous for a nucleotide substitution in exon 6 (c.544C>T) and another subject was found to be heterozygous for a C>T transition in exon 9 (c.802C>T). Both mutations introduce a prema…

MaleHyperlipoproteinemiasMessengerDNA Mutational Analysismedicine.disease_causeExonFamilial hyperalphalipoproteinemiaChlorocebus aethiopsCETP activity; CETP gene mutations; Familial hyperalphalipoproteinemia; HDL size; Adolescent; Adult; Aged; Animals; Biomarkers; COS Cells; Cercopithecus aethiops; Cholesterol Ester Transfer Proteins; Cholesterol HDL; DNA Mutational Analysis; European Continental Ancestry Group; Female; Humans; Hyperlipoproteinemias; Italy; Male; Middle Aged; Phenotype; RNA Messenger; Transfection; Up-Regulation; Young Adult; Mutation; Cardiology and Cardiovascular MedicineGeneticsMutationTransition (genetics)biologyCETP activityMiddle AgedUp-RegulationCholesterolPhenotypeItalyCOS CellsRNA splicingFemaleFamilial hyperalphalipoproteinemia; CETP gene mutations; CETP activity; HDL sizelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultHDLAdolescentEuropean Continental Ancestry GroupSocio-culturaleHDL sizeTransfectionWhite PeopleCercopithecus aethiopsYoung AdultCETP gene mutationsCholesterylester transfer proteinmedicineAnimalsHumansRNA MessengerGeneAgedCholesterol HDLIntroncetpCholesterol Ester Transfer Proteinscarbohydrates (lipids)biology.proteinRNAmutationBiomarkersMinigene
researchProduct

Behaviour of the neutrophil to lymphocyte ratio in young subjects with acute myocardial infarction

2016

In the last years the neutrophil to lymphocyte ratio (NLR) has been examined in cardiovascular disorders and in particular in coronary artery disease and acute myocardial infarction (AMI). Now we examined this parameter in subjects with juvenile myocardial infarction at the initial stage and after 3 and 12 months. We enrolled 123 young subjects (112 men and 11 women, mean age 39.4 ± 5.8 yrs) with AMI. The time interval between the AMI onset and the investigation was 13 ± 7 days. The mean value of NLR observed in young AMI subjects was significantly increased compared to normal controls (N = 1.817 ± 0.711; young AMI subjects = 2.376 ± 0.873, p <  0.0001). NLR does not discriminate STEMI (2.4…

MaleNeutrophilsPhysiologyLymphocyteMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyCoronary artery diseaseLeukocyte Count0302 clinical medicineRetrospective StudieRisk FactorsMedicineLymphocytes030212 general & internal medicineMyocardial infarctionStage (cooking)HematologyNeutrophilSmokingJuvenile myocardial infarction; leukocyte count; neutrophil/lymphocyte ratio; Adult; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Humans; Inflammation; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myocardial Infarction; Neutrophils; Prognosis; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Smoking; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)HematologyMiddle AgedPrognosismedicine.anatomical_structureAbsolute neutrophil countCardiologyLymphocyteFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosi03 medical and health sciencesPhysiology (medical)Internal medicineHumansLymphocyte Countcardiovascular diseasesNeutrophil to lymphocyte ratioRetrospective StudiesInflammationbusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseJuvenile myocardial infarctionneutrophil/lymphocyte ratioST Elevation Myocardial InfarctionbusinessBiomarkersClinical Hemorheology and Microcirculation
researchProduct

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

2010

Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); …

MaleNitric Oxide Synthase Type IIlcsh:ChemistryUbiquitinNeurotoxinlcsh:QH301-705.5Receptor Notch3SpectroscopyNeuronsReceptors NotchbiologyGlial fibrillary acidic proteinMicrofilament ProteinsGeneral MedicineComputer Science ApplicationsCell biologySubstantia NigraNitric oxide synthaseNeuroprotective Agentsmedicine.anatomical_structureBiochemistryNeurogliaNeurogliaMethylhydrazinesneuroimmunological biomarkersTyrosine 3-Monooxygenasesmall moleculeSubstantia nigraParkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small moleculeNeuroprotectionArticleCatalysisInorganic ChemistryGlial Fibrillary Acidic ProteinmedicineAnimalsParkinson Disease SecondaryRats WistarPhysical and Theoretical ChemistryOxidopamineMolecular BiologyTyrosine hydroxylase6-OHDA modelCalcium-Binding ProteinsmildronateOrganic ChemistryCorpus StriatumRatslcsh:Biology (General)lcsh:QD1-999nervous systemParkinson’s diseasebiology.proteinBiomarkersInternational Journal of Molecular Sciences
researchProduct

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

2015

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of comp…

MaleOncogene Proteins Fusionmedicine.medical_treatmentDrug ResistancePhases of clinical researchSalvage therapyKaplan-Meier EstimatePharmacologyGastroenterologyBenzoatesArsenicalschemistry.chemical_compoundLeukemia Promyelocytic AcuteRecurrenceAntineoplastic Combined Chemotherapy ProtocolsMedicineArsenic trioxidePromyelocyticOncogene ProteinsTumorLeukemiaRemission InductionHematopoietic Stem Cell TransplantationCell DifferentiationOxidesclinical trialHematologyMiddle AgedCombined Modality Therapyall-trans retinoic acidarsenic trioxideLeukemiaCardiovascular DiseasesFemalemedicine.drugAdultmedicine.medical_specialtyTetrahydronaphthalenesAcute promyelocytic leukaemia; all-trans retinoic acid; arsenic trioxide; clinical trial; tamibarotene; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia Promyelocytic Acute; Male; Middle Aged; Oncogene Proteins Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; TretinoinAntineoplastic AgentsTretinoinAcuteArticleDisease-Free SurvivalTretinoinInternal medicineBiomarkers TumorHumansFusionneoplasmsAgedFebrile NeutropeniaSalvage TherapyChemotherapybusiness.industrymedicine.diseasetamibaroteneAcute promyelocytic leukaemiaConsolidation ChemotherapychemistryDrug Resistance NeoplasmNeoplasmTamibarotenebusinessSettore MED/15 - Malattie del SangueFebrile neutropeniaBiomarkers
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

2021

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover, most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity within inclusion criteria and follow-up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work a…

MaleOncologymedicine.medical_specialtyQH301-705.5clinical biomarkers030232 urology & nephrologyReviewIndependent predictorCatalysisInorganic Chemistry03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineDaily practicemedicineHumansBiology (General)Physical and Theoretical ChemistryOverdiagnosisWatchful WaitingQD1-999Molecular BiologyPathologicalSpectroscopybusiness.industryOrganic Chemistryactive surveillanceProstatic NeoplasmsCancerGeneral Medicinemedicine.diseaseprostate cancerComputer Science ApplicationsChemistryUrine biomarkers030220 oncology & carcinogenesisDisease Progressionrisk predictorsbusinessBiomarkersClinical progressionInternational Journal of Molecular Sciences
researchProduct

Accelerometer-assessed sedentary work, leisure time and cardio-metabolic biomarkers during one year : Effectiveness of a cluster randomized controlle…

2017

BackgroundIt is unknown whether reducing sedentary time at work and during leisure time is possible and effective during one year.MethodsOffice workers with young children were recruited for this one-year cluster-randomized controlled trial through kindergartens and primary schools from 7 clusters in the city of Jyväskylä, Finland. After a lecture, face-to-face tailored counseling was used to set contractually binding goals regarding reducing and breaking up sitting periods and increasing light intensity physical activity during work and leisure time. Primary outcomes of total, work and leisure sedentary time (ResultsParticipants from intervention (N = 71) and control (N = 62) regions were …

MaleParentscardio-metabolic biomarkersLeisure timeSocial Sciencessedentary workbiomarkkeritCardiovascular SystemBiochemistrylaw.invention0302 clinical medicineRandomized controlled trialSociologylawMedicine and Health SciencesCluster AnalysisPublic and Occupational Health030212 general & internal medicineta315Musculoskeletal SystemMultidisciplinaryQRta3142vanhemmatLecturesEngineering and TechnologyLegsMedicineFemaleAnatomyBehavioral and Social Aspects of Healthfyysinen aktiivisuusvapaa-aikaResearch ArticleAdultmedicine.medical_specialtyScienceAccelerationSittingEducation03 medical and health sciencesmedicineHumansistumatyöOccupationsSedentary lifestyleNutritionBehaviorbusiness.industryWork (physics)Limbs (Anatomy)Biology and Life Sciences030229 sport sciencesPhysical ActivityAnthropometryDietleisure timeLight intensitymarkkeritLean body massPhysical therapyRecreationSedentary BehaviorElectronicsAccelerometersbusinessBiomarkers
researchProduct